LOS ANGELES, CA--(Marketwire - April 15, 2008) - Kythera Biopharmaceuticals, Inc. ("Kythera") announced today the initiation of a second Phase II clinical trial evaluating its proprietary product, ATX-101, for the reduction of unwanted submental (under chin) fat. This clinical trial is the second in a series of Phase II studies of ATX-101 in aesthetic applications and is aimed at assessing the safety and effectiveness of ATX-101 as a "liposculpting" agent. The clinical program aims to lead to registration of ATX-101 as an approved prescription drug in the U.S., Europe and Asia.
